コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ecific epigenetic dysregulation in a complex neuropsychiatric disorder.
2 ne encoding CaMKIIalpha linked to a specific neuropsychiatric disorder.
3 suggested that defective microglia cause the neuropsychiatric disorder.
4 Bipolar affective disorder is a common neuropsychiatric disorder.
5 isorder (ADHD) is a common, highly heritable neuropsychiatric disorder.
6 years, SD=11.40), of which 60 (19.7%) had a neuropsychiatric disorder.
7 he treatment of affective and stress-related neuropsychiatric disorders.
8 nce of deleterious variants segregating with neuropsychiatric disorders.
9 en implicated in developmentally originating neuropsychiatric disorders.
10 e involved in the pathophysiology of several neuropsychiatric disorders.
11 rphology are known in neurodevelopmental and neuropsychiatric disorders.
12 tive drugs for the treatment of a variety of neuropsychiatric disorders.
13 Akt1/3 mutant mice in behaviors relevant to neuropsychiatric disorders.
14 ing, while DG dysfunction is associated with neuropsychiatric disorders.
15 y in genes whose dysregulation is related to neuropsychiatric disorders.
16 iptome is now a phenotypic signature of many neuropsychiatric disorders.
17 s have been viewed as symptoms of associated neuropsychiatric disorders.
18 l oxytocinergic targets for the treatment of neuropsychiatric disorders.
19 ioid receptor (KOR) is implicated in various neuropsychiatric disorders.
20 st in the widespread use of animal models of neuropsychiatric disorders.
21 tal programming and the later development of neuropsychiatric disorders.
22 foresight and is symptomatic of a number of neuropsychiatric disorders.
23 el diseases, cancer, metabolic syndrome, and neuropsychiatric disorders.
24 etions in NRXN1 are strongly associated with neuropsychiatric disorders.
25 new therapeutic targets for the treatment of neuropsychiatric disorders.
26 development of gender-specific treatments of neuropsychiatric disorders.
27 ional and epigenetic studies with respect to neuropsychiatric disorders.
28 been associated with a wide range of complex neuropsychiatric disorders.
29 ntal cortex (mPFC) are implicated in several neuropsychiatric disorders.
30 ch for targeting GABA(B) receptor-associated neuropsychiatric disorders.
31 riant with high penetrance for developmental neuropsychiatric disorders.
32 e likely to confer female-specific risks for neuropsychiatric disorders.
33 a 27 (SCA27) and an emerging risk factor for neuropsychiatric disorders.
34 expected as a novel individual biomarker of neuropsychiatric disorders.
35 aberrant dendritic morphology characterizes neuropsychiatric disorders.
36 ng and quantification of synaptic density in neuropsychiatric disorders.
37 tic variations that contribute to a range of neuropsychiatric disorders.
38 pring negative-valence behaviors relevant to neuropsychiatric disorders.
39 at are elicited by these drugs used to treat neuropsychiatric disorders.
40 clinical activity in schizophrenia and other neuropsychiatric disorders.
41 treatment of nicotine addiction and several neuropsychiatric disorders.
42 ctor on the biological path from CT to adult neuropsychiatric disorders.
43 and may provide new multimodal biomarkers of neuropsychiatric disorders.
44 n between pollution exposure and the risk of neuropsychiatric disorders.
45 between environmental pollution and risk of neuropsychiatric disorders.
46 etter understanding of the role of D(4)Rs in neuropsychiatric disorders.
47 potential to revolutionize the treatment of neuropsychiatric disorders.
48 of these drugs were associated with various neuropsychiatric disorders.
49 ific regulation of genes implicated in major neuropsychiatric disorders.
50 lication of the hippocampus in developmental neuropsychiatric disorders.
51 may be a critical part of the development of neuropsychiatric disorders.
52 nd the constellation of symptoms observed in neuropsychiatric disorders.
53 observed in a wide range of neurological and neuropsychiatric disorders.
54 rain health and subsequent susceptibility to neuropsychiatric disorders.
55 e pathophysiology accounting for symptoms in neuropsychiatric disorders.
56 ent sensing, via MAVS, to treat dementia and neuropsychiatric disorders.
57 ctors contributing to neurodevelopmental and neuropsychiatric disorders.
58 er role in cognition and its disturbances in neuropsychiatric disorders.
59 variants have been reported in patients with neuropsychiatric disorders.
60 ber variation (CNV) is an important cause of neuropsychiatric disorders.
61 volume and shape are found in several common neuropsychiatric disorders.
62 ptor is an attractive therapeutic target for neuropsychiatric disorders.
63 it and which is vulnerable to impairments in neuropsychiatric disorders.
64 e pathophysiology of an increasing number of neuropsychiatric disorders.
65 ant spine morphology is associated with many neuropsychiatric disorders.
66 lator with known links to a wide spectrum of neuropsychiatric disorders.
67 tions for our understanding and treatment of neuropsychiatric disorders.
68 malities in regional CBF are present in many neuropsychiatric disorders.
69 in shaping the overall phenotypes of genetic neuropsychiatric disorders.
70 n (OT) is a potential treatment for multiple neuropsychiatric disorders.
71 d objectively defining subtypes within other neuropsychiatric disorders.
72 impacted during the course of developmental neuropsychiatric disorders.
73 urons in emotional deficits portending major neuropsychiatric disorders.
74 whereby neuroligin-3 mutations contribute to neuropsychiatric disorders.
75 s, which are often observed in patients with neuropsychiatric disorders.
76 esistant epileptic seizures, and more severe neuropsychiatric disorders.
77 nificantly overlap with loci associated with neuropsychiatric disorders.
78 a vulnerable target of many neurological and neuropsychiatric disorders.
79 l process in the trajectory of developmental neuropsychiatric disorders.
80 rment in this development is associated with neuropsychiatric disorders.
81 replicable susceptibility genes for several neuropsychiatric disorders.
82 cium channels, are often mutated in multiple neuropsychiatric disorders.
83 nction in specific subtypes is implicated in neuropsychiatric disorders.
84 dissection of neural circuits implicated in neuropsychiatric disorders.
85 Oxytocin may have promise as a treatment for neuropsychiatric disorders.
86 ations of the two can be sufficient to cause neuropsychiatric disorders.
87 o behavioural and health outcomes, including neuropsychiatric disorders.
88 approaches for the treatment of a variety of neuropsychiatric disorders.
89 d to discover unknown neuronal phenotypes of neuropsychiatric disorders.
90 ened risks for the subsequent development of neuropsychiatric disorders.
91 rogate this network in preclinical models of neuropsychiatric disorders.
92 genetic variations that are associated with neuropsychiatric disorders.
93 or the treatment of symptoms associated with neuropsychiatric disorders.
94 potential targets for improving treatment of neuropsychiatric disorders.
95 re effective brain stimulation therapies for neuropsychiatric disorders.
96 and their dysfunction associates with severe neuropsychiatric disorders.
97 tion, and its dysfunction is associated with neuropsychiatric disorders.
98 to further our etiological understanding of neuropsychiatric disorders.
99 and a therapeutic lead for the treatment of neuropsychiatric disorders.
100 erplay between blunted empathic behavior and neuropsychiatric disorders.
101 to improve our mechanistic understanding of neuropsychiatric disorders.
102 thickness in previously published studies of neuropsychiatric disorders.
103 s its genetic and biological relationship to neuropsychiatric disorders.
104 ave identified numerous loci associated with neuropsychiatric disorders.
105 tic agents for treatment of ciliopathies and neuropsychiatric disorders.
106 r disorder, and its overlap with other major neuropsychiatric disorders.
107 sychiatric, medication and family history of neuropsychiatric disorders.
108 rebrain development, including signatures of neuropsychiatric disorders.
109 ormal function and significantly impaired in neuropsychiatric disorders.
110 itive processing that characterizes numerous neuropsychiatric disorders.
111 TS are complex and often overlap with other neuropsychiatric disorders.
112 AT), and is implicated in several DA-related neuropsychiatric disorders.
113 A-dependent processes including a variety of neuropsychiatric disorders.
114 tion and elucidating striatal dysfunction in neuropsychiatric disorders.
115 ions (CNVs) that predispose to developmental neuropsychiatric disorders.
116 eceptor hypofunction associated with certain neuropsychiatric disorders.
117 ABAergic neuron gene expression and multiple neuropsychiatric disorders.
118 ary to improve treatments for stress-related neuropsychiatric disorders.
119 2 and associated to several neurological and neuropsychiatric disorders.
120 sts with myriad symptoms, including multiple neuropsychiatric disorders.
121 ns marked by deficient inhibition, including neuropsychiatric disorders.
124 ned aggression is characteristic of multiple neuropsychiatric disorders and can have various negative
126 regulation of neuronal function relevant to neuropsychiatric disorders and clarify the role of Kctd1
127 has been implicated in a surprising range of neuropsychiatric disorders and cognitive and affective f
128 dings of human postmortem genomic studies of neuropsychiatric disorders and comparable animal models
130 based on large-scale GWAS data for different neuropsychiatric disorders and cortical brain measures,
131 MIs for restoring lost emotional function in neuropsychiatric disorders and for probing the neural me
133 fects in pathways previously associated with neuropsychiatric disorders and indications of interactio
134 and chronic stress, correlate with offspring neuropsychiatric disorders and inflammation, respectivel
135 ociations between T.gondii and various human neuropsychiatric disorders and outline how these may be
136 prenatal brain in susceptibility to various neuropsychiatric disorders and prioritize potential risk
137 variants is a key challenge in understanding neuropsychiatric disorders and will open an avenue in th
138 creasingly associated with a wide variety of neuropsychiatric disorders and, more recently, causal fr
139 dical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic infl
140 ades the broad role of opioids in addiction, neuropsychiatric disorders, and pain states has been som
141 coexpressed networks of genes implicated in neuropsychiatric disorders, and the expression of these
142 e of the earliest SNPs to be associated with neuropsychiatric disorders, and the underlying molecular
143 in adolescence or young adulthood, including neuropsychiatric disorders; and the Charlson Comorbidity
144 Neurodegenerative, neurodevelopmental and neuropsychiatric disorders are among the greatest public
147 c cell adhesion molecules that are linked to neuropsychiatric disorders, are extensively studied, but
148 Conditional analysis reveals that distinct neuropsychiatric disorders associate with distinct sets
149 rders, a concept termed pediatric autoimmune neuropsychiatric disorders associated with streptococcal
151 e and epigenome, with disruptions in several neuropsychiatric disorder-associated pathways and gene f
152 this approach to GWAS data from two related neuropsychiatric disorders-autism spectrum disorder and
153 es across patients diagnosed with four major neuropsychiatric disorders: autism spectrum condition (A
154 g unique insights about sexual dimorphism in neuropsychiatric disorders, awareness of the increased r
155 cted attention as a genetic model for common neuropsychiatric disorders because of its association wi
156 ic saccadic responses are a hallmark of many neuropsychiatric disorders, but how this process is impl
157 understanding of the genetic architecture of neuropsychiatric disorders, but it has also led to a bro
158 unity to elucidate the mechanisms underlying neuropsychiatric disorders by investigating the pathophy
160 Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized by repetitive mo
163 ovide potential targets for the treatment of neuropsychiatric disorders characterized by cognitive in
164 er (ASD) encompasses a collection of complex neuropsychiatric disorders characterized by deficits in
165 sfunction is associated with a wide range of neuropsychiatric disorders commonly treated pharmacologi
166 early life inflammation as risk factors for neuropsychiatric disorders compels us to consider whethe
167 n this gene are associated with a variety of neuropsychiatric disorders consistent with its postsynap
169 This work demonstrates increased rates of neuropsychiatric disorders [e.g., increased autism spect
170 ship between ciliary protein dysfunction and neuropsychiatric disorders, for e.g. interconnections of
171 ns are implicated in the pathology of severe neuropsychiatric disorders, for which effective treatmen
174 ve functions in people with neurological and neuropsychiatric disorders has been a major goal of psyc
175 autoantibodies against neuronal receptors in neuropsychiatric disorders has fostered new conceptual a
176 h for the genetic factors underlying complex neuropsychiatric disorders has proceeded apace in the pa
178 y, genome-wide association studies (GWAS) of neuropsychiatric disorders have identified a risk locus
179 epistatic events and genetic interactions in neuropsychiatric disorders, how paradigm shifts in the p
180 n addition, OCD is an important example of a neuropsychiatric disorder in which rigorous research on
181 t provide insight into mechanisms underlying neuropsychiatric disorders in 22q11.2 deletion syndrome
182 ical mechanisms underlying the expression of neuropsychiatric disorders in 22q11.2 deletion syndrome,
185 mice and have been reported to be related to neuropsychiatric disorders in humans and mouse models, s
186 alanin has been implicated in stress-related neuropsychiatric disorders in humans and rodent models.
187 s its relationship to novel therapeutics for neuropsychiatric disorders in humans, and conclude by re
193 be relevant to the pathophysiology of these neuropsychiatric disorders in the general population.
194 tly under investigation for the treatment of neuropsychiatric disorders including Alzheimer's disease
195 ) in the brain has been detected in numerous neuropsychiatric disorders including Alzheimer's disease
196 variants of NSSs are associated with several neuropsychiatric disorders including attention deficit h
197 nction is believed to contribute to multiple neuropsychiatric disorders including attention-deficit/h
198 l affiliation are central features of severe neuropsychiatric disorders including autism spectrum dis
199 diet during pregnancy and offspring risk for neuropsychiatric disorders including depression, anxiety
200 n being considered as a therapeutic for many neuropsychiatric disorders including depression, anxiety
201 le promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety
202 s also associated with an increased risk for neuropsychiatric disorders including schizophrenia and a
203 tion, which is involved in a wide variety of neuropsychiatric disorders including traumatic brain inj
204 the DA system are implicated in a number of neuropsychiatric disorders, including attention deficit
205 d amphetamine-and plays an important role in neuropsychiatric disorders, including attention-deficit
206 3.3 microdeletion is associated with several neuropsychiatric disorders, including autism and schizop
208 e suggests that a number of neurological and neuropsychiatric disorders, including chronic pain, may
209 ess affected in a number of neurological and neuropsychiatric disorders, including fragile X syndrome
210 sregulation is a hallmark symptom of several neuropsychiatric disorders, including generalized anxiet
211 etion that is associated with a high risk of neuropsychiatric disorders, including intellectual disab
212 is characteristically disrupted in multiple neuropsychiatric disorders, including major depressive d
213 stimulation (DBS) is used to treat multiple neuropsychiatric disorders, including Parkinson's Diseas
214 exposure towards increased vulnerability to neuropsychiatric disorders, including posttraumatic stre
215 essed throughout limbic circuits affected in neuropsychiatric disorders, including prefrontal cortex
216 e decision making is associated with several neuropsychiatric disorders, including problem gambling a
217 ic parasite, is increasingly being linked to neuropsychiatric disorders, including schizophrenia, Alz
218 C spontaneous default activity is altered in neuropsychiatric disorders, including schizophrenia-a di
219 (MIA) is a proposed risk factor for multiple neuropsychiatric disorders, including schizophrenia.
220 alience network (SN) is dysregulated in many neuropsychiatric disorders, including substance use diso
221 nd are implicated in the etiology of several neuropsychiatric disorders, including substance use diso
222 could lead to novel treatment strategies for neuropsychiatric disorders involving OFC dysfunction.
223 ment and sex to impart risk for multifaceted neuropsychiatric disorders is also unlikely to be unders
225 pigenetic variation of non-coding regions in neuropsychiatric disorders is increasingly appreciated,
227 (MFC) centrally implicated in several major neuropsychiatric disorders, it is critical to understand
228 idered as a promising therapeutic target for neuropsychiatric disorders; its pharmacology, however, r
230 nical studies indicate it is dysregulated in neuropsychiatric disorders like autism and addiction, ma
231 ns and have also been implicated in multiple neuropsychiatric disorders like fragile X syndrome, auti
232 osure (PCE) predisposes offspring to various neuropsychiatric disorders linked to aberrant dopaminerg
233 des could explain the neurodevelopmental and neuropsychiatric disorders observed in mice and humans w
235 al circuits and are associated with numerous neuropsychiatric disorders, particularly drug abuse and
236 lap between MND, frontotemporal dementia and neuropsychiatric disorders, particularly mood disorders.
237 subcortical circuits and are associated with neuropsychiatric disorders, particularly substance use d
239 ric history, medication or family history of neuropsychiatric disorders predicted cognitive and/or be
241 he risk for offspring neurodevelopmental and neuropsychiatric disorders, prompting critical examinati
242 has been associated with a broad spectrum of neuropsychiatric disorders, prompting investigations int
243 mote the development of novel treatments for neuropsychiatric disorders related to prefrontal E/I imb
244 e a neurogenetic framework for understanding neuropsychiatric disorders related to reproductive hormo
246 jority of common risk alleles identified for neuropsychiatric disorders reside in noncoding regions o
247 relationships, and test whether dystonia and neuropsychiatric disorders share a genetic relationship.
248 uptions observed in idiopathic developmental neuropsychiatric disorders.SIGNIFICANCE STATEMENT Invest
249 promote emergence of schizophrenia and other neuropsychiatric disorders.SIGNIFICANCE STATEMENT The ac
250 nt role for integrins in modulating risk for neuropsychiatric disorders.SIGNIFICANCE STATEMENT The in
251 y-inhibitory imbalance often associated with neuropsychiatric disorders.SIGNIFICANCE STATEMENT Voltag
252 ompared with subcortical findings from other neuropsychiatric disorders studied by the ENIGMA consort
254 mber of the GPCR family and is implicated in neuropsychiatric disorders such as anxiety and depressio
255 errant neuronal wiring often associated with neuropsychiatric disorders such as autism or schizophren
257 ppetitive, and aversive behavior, as well as neuropsychiatric disorders such as Parkinson's disease,
258 rant genetic risk variants for developmental neuropsychiatric disorders such as schizophrenia (SCZ) a
259 disruption has recently been associated with neuropsychiatric disorders such as schizophrenia and aut
260 is an important target for the treatment of neuropsychiatric disorders such as schizophrenia and Par
261 White matter abnormalities are prevalent in neuropsychiatric disorders such as schizophrenia, but it
265 f allosteric modulators for neurological and neuropsychiatric disorders, such as autism, cognitive im
266 ted in multiple human neurodevelopmental and neuropsychiatric disorders, such as autism, schizophreni
267 ation of the human brain serotonin system in neuropsychiatric disorders, such as major depression and
270 problems, collectively termed TSC-Associated Neuropsychiatric Disorders (TAND), and the cell types re
272 IGNIFICANCE STATEMENT Cocaine addiction is a neuropsychiatric disorder that is detrimental to society
273 stress, and E/I imbalance occurs in numerous neuropsychiatric disorders that co-occur with chronic st
274 ing normal brain development, as well as the neuropsychiatric disorders that emerge in this vulnerabl
275 e major diagnostic symptoms in a spectrum of neuropsychiatric disorders that include schizophrenia, o
276 rain calcification, an autosomally inherited neuropsychiatric disorder, the presence of bilateral bra
277 cated across multiple neurodevelopmental and neuropsychiatric disorders, there has been considerable
280 considerable progress has been made linking neuropsychiatric disorders to genetic underpinnings.
284 To better understand the role of CREs in neuropsychiatric disorders we applied the Assay for Tran
285 es, from the synaptic to the behavioural, in neuropsychiatric disorders where decision-making biases
286 gnitive decline and cognitive impairments in neuropsychiatric disorders where dopamine signalling is
287 m of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most s
288 phase 1 clinical trials for the treatment of neuropsychiatric disorders wherein dynorphin is thought
289 rms an important framework for understanding neuropsychiatric disorders, which are proposed to be the
290 e results have implications for treatment of neuropsychiatric disorders, which may be characterized b
291 -compulsive disorder (OCD) is a debilitating neuropsychiatric disorder with a genetic risk component,
292 mpulsive disorder (OCD) is a severe, chronic neuropsychiatric disorder with a strong genetic componen
295 ted.Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder with symptoms including intrus
296 or pharmacological manipulation of Cav1.2 in neuropsychiatric disorders with developmental and/or str
297 spectrum disorders (ASDs) are developmental neuropsychiatric disorders with heterogeneous etiologies
298 stinction of susceptibility to BD from other neuropsychiatric disorders with overlapping clinical tra
299 Dysregulation of inhibition can lead to neuropsychiatric disorders, yet little is known about th
300 r incidence is among the most extreme of all neuropsychiatric disorders, yet the origins of the sex d